RFA
AUPH icon

Reilly Financial Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Reilly Financial Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100
Closed – – 918
2016
Q4 		$0 Buy
+100
New +$322 ﹤0.01% 833

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CLCM
Crawford Lake Capital Management Lakewood, New Jersey $87.4M AUM 30.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Reilly Financial Advisors's AUPH Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2017, closing a stake of 100 shares.

Reilly Financial Advisors first reported a position in AUPH in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 71 funds tracked by Wall St. Rank hold AUPH as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Aurinia Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 100 Aurinia Pharmaceuticals shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Reilly Financial Advisors's Aurinia Pharmaceuticals position peaked at $0 in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.